Aditya Puri to Chair the Board of Stelis Biopharma, the proposed demerged Biotech Business of Strides
Posted On: 2021-02-04 01:37:49 (Time Zone: Arizona, USA)
Strides Pharma Science Limited (Strides) today announced that the Board of Directors of the Company have approved in principle the demerger of its biotech business under Stelis Biopharma (Stelis). The demerger is expected to unlock significant value for Strides shareholders.
The Board will form a Committee of Directors to explore various options of value discovery including listing of the business on a standalone basis. The Committee will recommend the proposals to the Audit Committee, Committee of Independent Directors and Board including the Scheme, swap ratio and way forward.
Aditya Puri joins as advisor to the Strides Group & Director of Stelis Biopharma equitybulls.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from equitybulls.com Daily Mail and Mail on Sunday newspapers.
Former HDFC Bank MD Aditya Puri joins biopharma company Strides as advisor
Aditya Puri said that he was looking forward to working with Kumar and building world-class institutions to produce high-quality affordable biotherapeutics and CDMO services
BusinessToday.In | January 8, 2021 | Updated 13:51 IST
Aditya Puri joins biopharma group as advisor
Former HDFC Bank Managing Director Aditya Puri has joined Strides Group as Advisor and Stelis Biopharma Bengaluru as Director. Strides Pharma Science Limited is pleased to announce that eminent corporate doyen Aditya Puri joins the Strides Group as an Advisor and also will be a Director of its associate Company, Stelis Biopharma, announced the company.
Strides receives USFDA approval for Oxybutynin Chloride Tablets
Posted On: 2020-12-18 02:41:57 (Time Zone: Arizona, USA)
Strides Pharma Science Limited (Strides) today announced that its step-down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received approval for Oxybutynin Chloride Tablets USP, 5 mg from the United States Food & Drug Administration (USFDA). The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Ditropan Tablets, 5 mg, of Janssen Pharmaceuticals, Inc.
According to IQVIA MAT October 2020 data, the US market for Oxybutynin Chloride Tablets USP, 5 mg is approximately US$ 29 Mn. The product will be manufactured at the company s flagship facility at Bengaluru and will be marketed by Strides Pharma Inc. in the US market.